Osteogenic potential and responsiveness to leptin of mesenchymal stem cells between postmenopausal women with osteoarthritis and osteoporosis.
The aim of this study was to compare the osteogenic potential and responsiveness to leptin of mesenchymal stem cells (MSCs) from bone marrow between postmenopausal women with osteoarthritis (OA) and osteoporosis (OP). MSCs of the proximal femur from OA and OP donors were cultured under control and different experimental mediums. After verifying the availability of primary cells, their osteogenic potential and responsiveness to leptin were compared between two groups. Similar patterns of cell growth were shown in both OA and OP groups. However, after the sixth passage, the viability of undifferentiated cells decreased more in OP than in OA donors. Under the same osteogenic supplements condition, the mRNA expression of osteogenesis-specific genes, osteocalcin (OC) and alkaline phosphatase (ALP) were higher in OA group. Comparison of bone matrix mineralization was parallel to that of mRNA expression. The level of bone-specific ALP (BAP) was higher in cells from donors with OA, whereas osteoprotegerin (OPG) was higher in OP group. This difference in BAP expression proved to be insignificant after the administration of leptin. Although leptin upregulated the expression of OPG, a significant difference still existed between OA and OP. In conclusion, differential osteogenic potential and responsiveness to leptin of MSCs were noted between postmenopausal women with OA and OP. Differential biological behavior of MSCs seems to be partly related to the different distribution of bone mass between OA and OP populations.
Zhang
Zi-Ming
ZM
Department of Orthopaedic Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China.
Jiang
Lei-Sheng
LS
Jiang
Sheng-Dan
SD
Dai
Li-Yang
LY
D050156:Adipogenesis / Q000187:drug effects; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000096:biosynthesis; D002113:Calcification, Physiologic / Q000187:drug effects; D002454:Cell Differentiation / Q000502:physiology; D002478:Cells, Cultured; D024042:Collagen Type I / Q000096:biosynthesis; D005260:Female; D006620:Hip Fractures / Q000503:physiopathology; D006801:Humans; D020738:Leptin / Q000494:pharmacology / Q000502:physiology*; D008071:Lipoprotein Lipase / Q000096:biosynthesis; D059630:Mesenchymal Stem Cells / Q000187:drug effects* / Q000378:metabolism; D010003:Osteoarthritis / Q000503:physiopathology*; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000503:physiopathology*; D047495:PPAR gamma / Q000096:biosynthesis; D017698:Postmenopause / Q000502:physiology*
D024042:Collagen Type I; D020738:Leptin; D047495:PPAR gamma; D008071:Lipoprotein Lipase; D000469:Alkaline Phosphatase